ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus

Journal of Gastrointestinal Surgery

Volumn 12, Issue 11, 2008, Pages 1815-1821

  Brabender, Jan ^a   Vallböhmer, Daniel ^a   Grimminger, Peter ^a   Hoffmann, Andreas C ^a   Ling, Frederike ^a   Lurje, Georg ^a   Bollschweiler, Elfriede ^a   Schneider, Paul M ^b   Hölscher, Arnulf H ^a   Metzger, Ralf ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Cancer of the esophagus; ERCC1; Molecular markers; Response prediction

Indexed keywords

DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; RNA; TUMOR MARKER;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD; CANCER INVASION; CANCER STAGING; EPIDEMIOLOGY; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; NONPARAMETRIC TEST; PATHOLOGY; PREDICTION AND FORECASTING; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; SURVIVAL; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; DNA-BINDING PROTEINS; ENDONUCLEASES; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA, NEOPLASM; ROC CURVE; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 54349093490     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-008-0668-7     Document Type: Article

References (24)

1. TN Walsh 1996 A comparison of multimodal therapy and surgery for esophageal adenocarcinoma N Engl J Med 335 7 462 467
2. CA Sherman 2002 Locally advanced esophageal cancer Curr Treat Options Oncol 3 6 475 485
3. SG Urba 2001 Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma J Clin Oncol 19 2 305 313
4. PM Schneider 2005 Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification Ann Surg 242 5 684 692
5. KK Wang M Wongkeesong NS Buttar 2005 American Gastroenterological Association medical position statement: role of the gastroenterologist in the management of esophageal carcinoma Gastroenterology 128 5 1468 1470
6. H Higashi 2006 Down-regulation of Gadd45 expression is associated with tumor differentiation in non-small cell lung cancer Anticancer Res 26 3A 2143 2147
7. FC Ling 2006 HIF-1alpha mRNA is not associated with histopathological regression following neoadjuvant chemoradiation in esophageal cancer Anticancer Res 26 6B 4505 4509
8. H Xi 2005 High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer Clin Cancer Res 11 23 8341 8347
9. U Warnecke-Eberz 2004 High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer Clin Cancer Res 10 11 3794 3799
10. U Warnecke-Eberz 2005 Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer Oncol Rep 13 6 1241 1246
11. F Miyazono 2004 Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer Br J Cancer 91 4 666 672
12. JP Hamilton 2006 Reprimo methylation is a potential biomarker of Barrett's-associated esophageal neoplastic progression Clin Cancer Res 12 22 6637 6642
13. AC Hoffmann 2007 Survivin mRNA in peripheral blood is frequently detected and significantly decreased following resection of gastrointestinal cancers J Surg Oncol 95 1 51 54
14. Y Shirota 2001 ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy J Clin Oncol 19 23 4298 4304
15. R Metzger 1998 ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy J Clin Oncol 16 1 309 316
16. RV Lord 2002 Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer Clin Cancer Res 8 7 2286 2291
17. W Schroder 2002 Frequency of nodal metastases to the upper mediastinum in Barrett's cancer Ann Surg Oncol 9 8 807 811
18. UE Gibson CA Heid PM Williams 1996 A novel method for real time quantitative RT-PCR Genome Res 6 10 995 1001
19. CA Heid 1996 Real time quantitative PCR Genome Res 6 10 986 994
20. CE Metz DJ Goodenough K Rossmann 1973 Evaluation of receiver operating characteristic curve data in terms of information theory, with applications in radiography Radiology 109 2 297 303
21. K Kawakami 2000 Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma J Natl Cancer Inst 92 22 1805 1811
22. H Usadel 2002 Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer Cancer Res 62 2 371 375
23. H Fiegl 2005 Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients Cancer Res 65 4 1141 1145
24. ML McCabe Z Dlamini 2005 The molecular mechanisms of oesophageal cancer Int Immunopharmacol 5 7-8 1113 1130